Podcast

Updates and Advances in the Treatment of Metastatic HER2+ Breast Cancer

Author(s):

OncLive Staff

Dr Pegram and colleagues focus on key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Related Videos
Alastair Thompson, BSc, MBChB, MD, FRCS
Adam M. Brufsky, MD, PhD, FACP
Sara M. Tolaney, MD, MPH
Chirag Shah, MD
Jason A. Mouabbi, MD
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Shipra Gandhi, MD
A panel of 5 experts on breast cancer
A panel of 5 experts on breast cancer
Related Content
Paolo Tarantino, MD, of Dana-Farber Cancer Institute
July 24th 2024

Pending Dato-DXd Approval Solidifies Importance of Sequencing in HR+ Breast Cancer

Nam Bui, MD, sarcoma specialist, clinical assistant professor, medicine, Stanford Cancer Institute; Ciara Kelly, MBBCh, BAO, interim clinical director, Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center
July 18th 2024

Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa

Lisa Conte
July 23rd 2024

Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy

Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, European Institute of Oncology
July 15th 2024

Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer

Sonya Reid, MD, MPH
July 22nd 2024

Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer

Pedram Razavi, MD, PhD
July 22nd 2024

Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management